Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: A preliminary report

被引:39
作者
Diamond, T
Ng, ATM
Levy, S
Magarey, C
Smart, R
机构
[1] ST GEORGE HOSP,DEPT SURG,SYDNEY,NSW 2217,AUSTRALIA
[2] ST GEORGE HOSP,DEPT NUCL MED,SYDNEY,NSW 2217,AUSTRALIA
关键词
estrogen therapy; parathyroid bone disease; parathyroidectomy;
D O I
10.1007/BF01623394
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Parathyroid surgery is indicated in patients presenting with primary hyperparathyroidism (PHPT) and osteoporosis (defined as bone mineral density more than 2 standard deviations below normal). Many are elderly women with complex medical problems, either unwilling or considered unfit for surgery. Estrogen replacement therapy (ERT) may potentially be an alternative form of therapy in this group. We studied 15 consecutive postmenopausal women presenting with PHPT and osteoporosis, Group 1 comprised 5 women who elected to be treated with ERT (conjugated equine estrogen, 0.3-0.625 mg/day). The other 10 women underwent successful parathyroidectomy. These 10 patients were randomly subdivided into group 2 (5 patients who received calcitriol 0.25 mu g b.i.d. for 12 months following surgery) and group 3 (5 patients who received elemental calcium 1 g/day for 12 months following surgery). Lumbar spine and femoral neck bone mineral density (BMD) were measured prior to and after 12 months of therapy, using a dual-energy Xray absorptiometer (Lunar DPX-L). The three groups did not differ with respect to their ages (group mean 71.8 years), or baseline serum calcium (group mean 2.77 mmol/l), serum parathyroid hormone (group mean 11.0 pmol/l), lumbar spine BMD (group mean 0.93 g/cm(2)) and femoral neck BMD (group mean 0.73 g/cm(2)) Serum calcium normalized in all patients who underwent surgery and none developed hypoparathyroidism. A non-significant decrease in serum calcium was seen in patients treated with ERT only. Lumbar spine (+5.3% per year; 95% CI, 1.1% to 9.6%) and femoral neck BMD (+5.5% per year; 95% CI, -2.1% to 13.2%) increased significantly after 12 months of ERT (p<0.001 compared with pre-therapy values). These increases in BMD did not differ significantly from those in patients who underwent successful parathyroidectomy followed by either calcitriol therapy or calcium replacement (lumbar spine BMD increase of +6.2% per year, 95% CI 3.1% to 9.4%; and femoral neck BMD increase of +3% per year, 95% CI 0 to 6%), In summary, increases in lumbar spine and femoral neck BMD occur following treatment of PHPT. ERT appeared as effective as parathyroidectomy (combined with either calcitriol or calcium supplements) for the treatment of osteoporosis in elderly postmenopausal women presenting with PHPT.
引用
收藏
页码:329 / 333
页数:5
相关论文
共 25 条
[1]  
[Anonymous], 1991, J Bone Miner Res, V6 Suppl 2, pS9
[2]   SEMINARS IN MEDICINE OF THE BETH-ISRAEL-HOSPITAL, BOSTON - CALCIUM-ION-SENSING CELL-SURFACE RECEPTORS [J].
BROWN, EM ;
POLLAK, M ;
SEIDMAN, CE ;
SEIDMAN, JG ;
RICCARDI, D ;
HEBERT, SC .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (04) :234-240
[3]   ESTROGEN PROTECTION AGAINST BONE RESORBING EFFECTS OF PARATHYROID-HORMONE INFUSION - ASSESSMENT BY USE OF BIOCHEMICAL MARKERS [J].
COSMAN, F ;
SHEN, V ;
XIE, F ;
SEIBEL, M ;
RATCLIFFE, A ;
LINDSAY, R .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (05) :337-343
[4]   CYCLICAL ETIDRONATE PLUS ERGOCALCIFEROL PREVENTS GLUCOCORTICOID-INDUCED BONE LOSS IN POSTMENOPAUSAL WOMEN [J].
DIAMOND, T ;
MCGUIGAN, L ;
BARBAGALLO, S ;
BRYANT, C .
AMERICAN JOURNAL OF MEDICINE, 1995, 98 (05) :459-463
[5]   TRABECULAR BONE REMODELING AND BALANCE IN PRIMARY HYPERPARATHYROIDISM [J].
ERIKSEN, EF ;
MOSEKILDE, L ;
MELSEN, F .
BONE, 1986, 7 (03) :213-221
[6]   POSTMENOPAUSAL BONE LOSS IS PREVENTED BY TREATMENT WITH LOW-DOSAGE ESTROGEN WITH CALCIUM [J].
ETTINGER, B ;
GENANT, HK ;
CANN, CE .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (01) :40-45
[7]   EFFECT OF ETHINYLESTRADIOL ON CALCIUM AND PHOSPHORUS METABOLISM OF POSTMENOPAUSAL WOMEN WITH PRIMARY HYPERPARATHYROIDISM [J].
GALLAGHER, JC ;
WILKINSON, R .
CLINICAL SCIENCE AND MOLECULAR MEDICINE, 1973, 45 (06) :785-802
[8]   PRIMARY HYPERPARATHYROIDISM - COMPREHENSIVE STUDY OF CLINICAL, BIOCHEMICAL AND RADIOGRAPHIC MANIFESTATIONS [J].
GENANT, HK ;
HECK, LL ;
LANZL, LH ;
ROSSMANN, K ;
VANDERHO.J ;
PALOYAN, E .
RADIOLOGY, 1973, 109 (03) :513-524
[9]   17-BETA-ESTRADIOL INHIBITS INTERLEUKIN-6 PRODUCTION BY BONE MARROW-DERIVED STROMAL CELLS AND OSTEOBLASTS INVITRO - A POTENTIAL MECHANISM FOR THE ANTIOSTEOPOROTIC EFFECT OF ESTROGENS [J].
GIRASOLE, G ;
JILKA, RL ;
PASSERI, G ;
BOSWELL, S ;
BODER, G ;
WILLIAMS, DC ;
MANOLAGAS, SC .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 89 (03) :883-891
[10]  
GREY AB, 1995, J BONE MINER RES, V10, pS153